Competition Bureau Reaches Consent Agreement in Medtronic/Covidien Deal
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 11/26/14 -- Competition Bureau
The Competition Bureau announced today that it has reached a consent agreement with Medtronic Inc. (Medtronic) and Covidien plc (Covidien) that resolves the Bureau''s concerns related to Medtronic''s proposed acquisition of Covidien. Both companies sell medical devices in Canada for the treatment of various conditions. The consent agreement filed with the Competition Tribunal today effectively resolves the Bureau''s finding that Medtronic''s acquisition of Covidien would likely result in a substantial prevention of competition in the supply of drug-coated balloons for the treatment of peripheral artery disease.
The agreement requires the sale of Covidien''s drug-coated balloon catheter (DCB) business, together with a perpetual, non-exclusive license to certain intellectual property. DCBs offer an emerging, innovative treatment method to clear blocked arteries.
The DCB business will be sold to The Spectranetics Corporation (Spectranetics), within 10 days of completing the proposed transaction. While negotiating the consent agreement, Medtronic and Covidien sought potential purchasers for the DCB business, and proposed Spectranetics. Upon a careful review, the Bureau determined that Spectranetics was committed to carrying on the DCB business and had the managerial, operational and financial capability to effectively compete in Canada, thereby resolving the likely prevention of competition.
A monitor has been appointed to ensure the completion of the sale of the DCB business and the transfer of certain pending approvals required to bring the device to market in Canada, including patent applications.
Throughout the review, the Bureau worked closely with other jurisdictions including the United States Federal Trade Commission (U.S. FTC). As the assets being divested are primarily located in the United States, but serve both the U.S. and Canadian markets, the Bureau coordinated with the U.S. FTC to ensure an effective remedy in both jurisdictions.
Quick Facts
Quotes
"This review is another example of how parties can work effectively to resolve the Bureau''s concerns. I am satisfied that the sale of the drug-coated balloon catheter business to Spectranetics will ensure that competition is preserved in the sale of medical devices for the treatment of peripheral vascular diseases."
Related Information
Position Statement:
Associated Links
A copy of the consent agreement will be available shortly on the .
/
The Competition Bureau, as an independent law enforcement agency, ensures that Canadian businesses and consumers prosper in a competitive and innovative marketplace.
Contacts:
For media enquiries, please contact:
Media Relations
819-994-5945
For general enquiries, please contact:
Information Centre
Competition Bureau
819-997-4282 / Toll free: 1-800-348-5358
TTY (hearing impaired): 1-800-642-3844
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.11.2014 - 13:46 Uhr
Sprache: Deutsch
News-ID 1321453
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
Government & Administration
Anmerkungen:
Diese Pressemitteilung wurde bisher 203 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Competition Bureau Reaches Consent Agreement in Medtronic/Covidien Deal
"
steht unter der journalistisch-redaktionellen Verantwortung von
Competition Bureau Canada (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
